Last reviewed · How we verify

E. Coli Complicated Appendicitis — Treatment Landscape & Competitive Intelligence

E. Coli Complicated Appendicitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating E. Coli Complicated Appendicitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Merrem Meropenem Pfizer meropenem 1996-01-01
Zosyn TAZOBACTAM Merck Sharp & Dohme B.V. beta Lactamase Inhibitor 1993-01-01
Merrem Merrem National Institutes of Health Clinical Center (CC) Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in E. Coli Complicated Appendicitis
  2. Merck Sharp & Dohme B.V. · 1 drug in E. Coli Complicated Appendicitis
  3. National Institutes of Health Clinical Center (CC) · 1 drug in E. Coli Complicated Appendicitis
  4. Pfizer · 1 drug in E. Coli Complicated Appendicitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in E. Coli Complicated Appendicitis:

Cite this brief

Drug Landscape (2026). E. Coli Complicated Appendicitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/e-coli-complicated-appendicitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing